Commonwealth Fund October 27, 2022


Medicare finally has the power to negotiate with pharmaceutical companies on prices for certain high-cost drugs, but what is the best approach for assessing a drug’s true clinical benefit?

While all methods for determining a drug’s value have their advantages and disadvantages, it’s important that Medicare’s process for choosing is transparent for all stakeholders

The Inflation Reduction Act (IRA), enacted in August 2022, empowers the Centers for Medicare and Medicaid Services (CMS) to negotiate directly with pharmaceutical companies to set the prices for a limited set of high-cost drugs covered by Medicare. However, the law does not detail a process for determining fair prices, other than a consideration for how long the drugs have been on the market.


Today's Sponsors


Today's Sponsor

Health Edge

Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Top Healthcare Industry Facts for 2023
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
States with the largest dual-eligible populations
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act
CMS proposes universal quality measures across all programs

Share This Article